Guardant Health, Inc. - GH STOCK NEWS

Guardant Health, a precision oncology company, launched the GuardantINFORM platform to enhance cancer drug development. This platform integrates clinical-genomic data from over 100,000 liquid biopsy tests, aiming to provide insights into tumor evolution and treatment resistance. Key applications include targeted drug development, clinical trial optimization, and post-marketing studies. The platform presents a significant opportunity for researchers in precision oncology, focusing on advanced solid tumors. However, Guardant Health warns that the platform's future potential is subject to various risks and uncertainties.

Guardant Health (Nasdaq: GH) presented new data at the AACR Virtual Annual Meeting II, demonstrating that its LUNAR-2 liquid biopsy achieves 90% sensitivity and 94% specificity in detecting early-stage colorectal cancer (CRC). Further analysis showed a specificity of 99% among controls negative for CRC by colonoscopy. These results highlight the potential of LUNAR-2 to enhance cancer screening rates, especially amid COVID-19 challenges. The assay is currently under evaluation in the ECLIPSE trial for average-risk adults.

Guardant Health (Nasdaq: GH) has appointed Vijaya Gadde to its Board of Directors, enhancing its leadership team. Gadde, currently Chief Legal Officer at Twitter, brings extensive experience in public policy and technology management. President AmirAli Talasaz emphasized her potential to guide the company's growth in precision oncology. Gadde expressed enthusiasm for contributing to Guardant's mission of improving cancer care through innovative data solutions, particularly in advanced cancer and early detection.

Guardant Health, a precision oncology company, announced the completion of a public offering of 13,225,000 shares of common stock at $84.00 per share, raising approximately $362.3 million in gross proceeds. Of these shares, 4,312,500 were sold by Guardant Health, while 8,912,500 were sold by SoftBank Investment Advisers. The net proceeds will primarily support corporate purposes, including working capital, sales, marketing, and capital expenditures. J.P. Morgan acted as the sole book-running manager for this offering.

Guardant Health has announced a public offering of 11,500,000 shares of its common stock priced at $84.00 per share, raising approximately $315 million before deductions. The offering was increased from an initial size of 10 million shares, with a 30-day option for underwriters to buy an additional 1,725,000 shares. The net proceeds will be used for general corporate purposes, including working capital and sales activities. The offering is expected to close on June 4, 2020, pending customary conditions.

Guardant Health has announced a proposed public offering of 10,000,000 shares of its common stock, with 3,000,000 shares being offered by the company and 7,000,000 shares by SoftBank Investment Advisers. An additional 1,500,000 shares may be available through an underwriter's option. The offering aims to raise funds primarily for general corporate purposes, including working capital and marketing activities. The offering is subject to market conditions and will not yield proceeds to Guardant Health from SoftBank's shares.

Guardant Health will participate in the William Blair Virtual Growth Stock Conference on June 11, 2020. The company's management is set to host a fireside chat at 10:00 a.m. Pacific Time. A live and archived webcast of the presentation will be available in the 'Investors' section of their website. Guardant Health is a leader in precision oncology, focusing on innovative blood tests and analytics to improve cancer care. The firm has introduced liquid biopsy tests such as Guardant360 and GuardantOMNI, which support advanced cancer treatment and early detection efforts.

Guardant Health (Nasdaq: GH) will present over 25 abstracts at the ASCO Annual Meeting and AACR Virtual Meeting, showcasing their blood tests for precision oncology. Key findings include Guardant360 and GuardantOMNI tests demonstrating high concordance with tissue biopsies. The LUNAR-2 liquid biopsy showed 90.3% sensitivity in detecting early-stage colorectal cancer, while data supports the use of ctDNA for drug development and monitoring. Ongoing trials include LUNAR-1, validating the clinical utility of liquid biopsy in adjuvant treatment for colon cancer.

Guardant Health, Inc. (Nasdaq: GH) reported first-quarter 2020 revenue of $67.5 million, an 84% increase year-over-year. The company performed 15,257 clinical tests, a 60% increase, and 5,266 biopharmaceutical tests, a 40% increase. Precision oncology revenue soared 109% due to rising testing volume and average price. However, operating expenses rose 75.1% to $81.9 million, leading to a net loss of $27.7 million. Guardant Health withdrew its 2020 financial guidance due to COVID-19 uncertainties. Cash reserves stood at $758.3 million.